KR101778603B1 - 3α-히드록시, 3β-메틸-5α-프레그난-20-온 (가낙솔론)의 제조 방법 - Google Patents

3α-히드록시, 3β-메틸-5α-프레그난-20-온 (가낙솔론)의 제조 방법 Download PDF

Info

Publication number
KR101778603B1
KR101778603B1 KR1020127006429A KR20127006429A KR101778603B1 KR 101778603 B1 KR101778603 B1 KR 101778603B1 KR 1020127006429 A KR1020127006429 A KR 1020127006429A KR 20127006429 A KR20127006429 A KR 20127006429A KR 101778603 B1 KR101778603 B1 KR 101778603B1
Authority
KR
South Korea
Prior art keywords
inert solvent
halide
methyl
methylating agent
titanium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127006429A
Other languages
English (en)
Korean (ko)
Other versions
KR20120084715A (ko
Inventor
케네스 쇼
알랜 허치슨
Original Assignee
마리누스 파마슈티컬스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마리누스 파마슈티컬스 filed Critical 마리누스 파마슈티컬스
Publication of KR20120084715A publication Critical patent/KR20120084715A/ko
Application granted granted Critical
Publication of KR101778603B1 publication Critical patent/KR101778603B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020127006429A 2009-08-13 2010-08-11 3α-히드록시, 3β-메틸-5α-프레그난-20-온 (가낙솔론)의 제조 방법 Active KR101778603B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23355309P 2009-08-13 2009-08-13
US61/233,553 2009-08-13
PCT/US2010/045176 WO2011019821A2 (en) 2009-08-13 2010-08-11 METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE)

Publications (2)

Publication Number Publication Date
KR20120084715A KR20120084715A (ko) 2012-07-30
KR101778603B1 true KR101778603B1 (ko) 2017-09-14

Family

ID=43586809

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127006429A Active KR101778603B1 (ko) 2009-08-13 2010-08-11 3α-히드록시, 3β-메틸-5α-프레그난-20-온 (가낙솔론)의 제조 방법

Country Status (14)

Country Link
US (1) US8362286B2 (https=)
EP (1) EP2464653B1 (https=)
JP (1) JP5745517B2 (https=)
KR (1) KR101778603B1 (https=)
CN (1) CN102549007B (https=)
AU (1) AU2010282570B2 (https=)
BR (1) BR112012003085B1 (https=)
CA (1) CA2769820C (https=)
EA (1) EA024269B1 (https=)
ES (1) ES2524724T3 (https=)
IL (1) IL217857A (https=)
MX (1) MX2012001728A (https=)
NZ (1) NZ597940A (https=)
WO (1) WO2011019821A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
US9629853B2 (en) 2014-05-21 2017-04-25 Wisconsin Alumni Research Foundation Uses of ganaxolone
CZ305837B6 (cs) * 2015-02-25 2016-03-30 Vysoká škola chemicko - technologická v Praze (3α,5β,20S)-3-Nitrooxy-pregnan-20-karboxylová kyselina
EA036155B1 (ru) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Инъекционные составы нейростероида, содержащие наночастицы
CN106366149B (zh) * 2016-08-09 2018-01-23 南京臣功制药股份有限公司 一种醋酸甲羟孕酮分散片的有关物质及其分析检测方法
CN106279326A (zh) * 2016-08-09 2017-01-04 南京臣功制药股份有限公司 一种醋酸甲羟孕酮胶囊的有关物质及其分析检测方法
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
IT201800009683A1 (it) * 2018-10-22 2020-04-22 Ind Chimica Srl Processo per la preparazione di 3α-idrossi-5α-pregnan-20-one (brexanolone)
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CN114728012A (zh) 2019-08-05 2022-07-08 马瑞纳斯制药公司 用于治疗癫痫持续状态的加奈索酮
JP7780431B2 (ja) 2019-12-06 2025-12-04 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
IT202000021316A1 (it) * 2020-09-09 2022-03-09 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953429A (en) 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
US6117994A (en) 1994-06-02 2000-09-12 Hoechst Marion Roussel Intermediates for 16β-methyl steroids
WO2006010085A1 (en) 2004-07-09 2006-01-26 Roxro Pharma, Inc. Use of neurosteroids to treat neuropathic pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
FI972202L (fi) * 1994-11-23 1997-07-17 Cocensys Inc Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
CN101583620B (zh) * 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953429A (en) 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
US6117994A (en) 1994-06-02 2000-09-12 Hoechst Marion Roussel Intermediates for 16β-methyl steroids
WO2006010085A1 (en) 2004-07-09 2006-01-26 Roxro Pharma, Inc. Use of neurosteroids to treat neuropathic pain

Also Published As

Publication number Publication date
AU2010282570B2 (en) 2014-04-24
EA024269B1 (ru) 2016-09-30
EP2464653A4 (en) 2013-01-16
JP5745517B2 (ja) 2015-07-08
EA201270241A1 (ru) 2013-09-30
CA2769820C (en) 2017-06-27
ES2524724T3 (es) 2014-12-11
AU2010282570A1 (en) 2012-02-23
HK1171761A1 (en) 2013-04-05
CA2769820A1 (en) 2011-02-17
IL217857A0 (en) 2012-03-29
IL217857A (en) 2016-03-31
JP2013501803A (ja) 2013-01-17
WO2011019821A3 (en) 2011-06-16
BR112012003085A2 (pt) 2020-12-01
CN102549007A (zh) 2012-07-04
EP2464653A2 (en) 2012-06-20
NZ597940A (en) 2013-03-28
BR112012003085B1 (pt) 2021-06-01
US8362286B2 (en) 2013-01-29
KR20120084715A (ko) 2012-07-30
US20110040112A1 (en) 2011-02-17
CN102549007B (zh) 2015-03-18
WO2011019821A2 (en) 2011-02-17
MX2012001728A (es) 2012-06-01
EP2464653B1 (en) 2014-10-22

Similar Documents

Publication Publication Date Title
KR101778603B1 (ko) 3α-히드록시, 3β-메틸-5α-프레그난-20-온 (가낙솔론)의 제조 방법
CN1829722B (zh) 区域选择性合成cci-779
CN105916846A (zh) 用于合成经保护的n-烷基三唑甲醛的三唑中间体
CN104379591A (zh) 用于制备2-脱氧-2-氟-2-甲基-d-呋喃核糖基核苷化合物的方法
JP2020528920A (ja) 胆汁酸類を製造するための方法
JP6100798B2 (ja) １６−置換型−１７−ケトステロイド類のアルキニル化方法
EP2596007A1 (en) Process for the preparation of 17-desoxy-corticosteroids
EP4201952A1 (en) Process for the controlled synthesis of voclosporin
JPH0637515B2 (ja) １７β アルカノイル ３−オキソ−４−アザ−５α−アンドロスト−１−エン類の新規な製造方法
CN105980396A (zh) 对映异构-孕酮及其中间体的合成
WO2010122096A1 (en) Process for obtaining fluorometholone and intermediates therefor
NO327095B1 (no) Fremgangsmate for fremstilling av 7alfa-metylsteroider
KR20160058722A (ko) ent-프로게스테론 및 그의 중간생성물의 합성
HK1171761B (en) METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE)
KR101251741B1 (ko) 칸데사르탄실렉세틸의 개선된 제조방법
CN112724015A (zh) 脂环族丙烯酸衍生物的制备方法及包括其的组合物
JP2024537848A (ja) 有機チタン化合物の製造方法
CN106414475A (zh) 生产21-甲氧基-11-β-苯基-19-去甲-孕甾-4, 9-二烯-3, 20-二酮衍生物的方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120312

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150810

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161220

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170622

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170908

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170911

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200624

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220622

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230626

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240624

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20250625

Start annual number: 9

End annual number: 9